Cover Image
市場調查報告書

脂肪代謝異常的開發中產品分析

Lipid Disorders - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 302506
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
脂肪代謝異常的開發中產品分析 Lipid Disorders - Pipeline Review, H1 2014
出版日期: 2014年05月15日 內容資訊: 英文 57 Pages
簡介

所謂的脂肪代謝異常,是指膽固醇·三酸甘油酯的數量達到異常的狀態的疾病。脂肪代謝異常和心血管疾病(尤其是心肌梗塞或心臟病發作)的發病風險上升有絕對的關係。主要症狀有伴隨血液中脂肪含量異常的皮膚、肌腱上脂肪沈積、血液中三酸甘油酯含量超高造成腹部內(肝臟、胰臟、腎臟等)疼痛、肥大化、發炎(朣脹)、脂質增加伴隨的眼球中血管遷移等。主要致病風險要素為年齡及抽煙、喝酒、肥胖、肝臟病、糖尿病、腎臟病等等。

本報告提供全球各國治療脂肪代謝異常的開發中產品開發情形相關分析,彙整產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,與最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

脂肪代謝異常概要

治療藥的開發

  • 脂肪代謝異常開發中產品:概要
  • 脂肪代謝異常開發中產品:比較分析

各企業開發中的脂肪代謝異常治療藥

大學/研究機關研究中的脂肪代謝異常治療藥

開發中的產品概要

  • 後期階段的產品
  • 初期階段的產品

脂肪代謝異常治療藥:開發中的產品一覽(各企業)

脂肪代謝異常治療藥:研究中的產品一覽(大學/研究機關別)

脂肪代謝異常治療藥的開發企業

  • Catabasis Pharmaceuticals, Inc.
  • Kythera Biopharmaceuticals, Inc.
  • Esperion Therapeutics, Inc.
  • Connexios Life Sciences Pvt. Ltd.

脂肪代謝異常:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 分子類別

藥物簡介

  • deoxycholic酸
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • Recombinant Protein for Atherosclerosis and Lipid Disorders
  • CNX-013-B2
  • 4-WF
  • CAT-2054
  • Small Molecules for Lipid Storage in Rare Disease

脂肪代謝異常治療藥:開發中產品的最新趨勢

脂肪代謝異常治療藥:暫停開發的產品

脂肪代謝異常相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全10件)

附錄

圖表一覽

目錄
Product Code: GMDHC5039IDB

Global Markets Direct's, 'Lipid Disorders - Pipeline Review, H1 2014', provides an overview of the Lipid Disorders's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lipid Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lipid Disorders and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Lipid Disorders
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Lipid Disorders and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Lipid Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Lipid Disorders pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Lipid Disorders
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Lipid Disorders pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lipid Disorders Overview
  • Therapeutics Development
    • Pipeline Products for Lipid Disorders - Overview
    • Pipeline Products for Lipid Disorders - Comparative Analysis
  • Lipid Disorders - Therapeutics under Development by Companies
  • Lipid Disorders - Therapeutics under Investigation by Universities/Institutes
  • Lipid Disorders - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Lipid Disorders - Products under Development by Companies
  • Lipid Disorders - Products under Investigation by Universities/Institutes
  • Lipid Disorders - Companies Involved in Therapeutics Development
    • Catabasis Pharmaceuticals, Inc.
    • Kythera Biopharmaceuticals, Inc.
    • Esperion Therapeutics, Inc.
    • Connexios Life Sciences Pvt. Ltd.
  • Lipid Disorders - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • deoxycholic acid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Atherosclerosis and Lipid Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CNX-013-B2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 4-WF - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAT-2054 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Lipid Storage in Rare Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lipid Disorders - Recent Pipeline Updates
  • Lipid Disorders - Dormant Projects
  • Lipid Disorders - Product Development Milestones
    • Featured News & Press Releases
      • Oct 07, 2013: KYTHERA Announces Additional Positive Efficacy and Patient Satisfaction Data From ATX-101 Phase III Trials for the Reduction of Submental Fat
      • Sep 16, 2013: KYTHERA Announces Positive ATX-101 Top Line Phase III Trial Results for the Reduction of Submental Fat
      • Aug 06, 2013: Piramal receives IND approval for P7435, its novel DGAT1 inhibitor for treatment of Lipid Disorders and Diabetes
      • Apr 13, 2013: Kythera Biopharma Presents Positive MRI Results From Phase IIb Study Of ATX-101 For Reduction Of Submental Fat At ASAPS 2013
      • Apr 06, 2013: Kythera Biopharma Announces Positive Interim Results From Phase IIIb Study Of ATX-101 At 11th Anti-Aging Medicine World Congress
      • Apr 05, 2013: Kythera Biopharma Enters Into Commercial Development And Supply Agreement With Cambridge Major Labs
      • Apr 04, 2013: Bayer's ATX-101 Significantly And Sustainably Reduces Unwanted Fat Under Chin
      • Mar 01, 2013: Kythera Biopharma Announces Positive Interim Results From Phase IIIb Study Of ATX-101 In Reduction Of Unwanted Submental Fat
      • Mar 01, 2013: Kythera Biopharma To Present New Data On ATX-101 At 2013 American Academy Of Dermatology Annual Meeting
      • Feb 01, 2013: Bayer Presents Results From Two Pivotal European Phase-III Studies Of ATX-101 At IMCAS
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Lipid Disorders, H1 2014
  • Number of Products under Development for Lipid Disorders - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Lipid Disorders - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2014
  • Lipid Disorders - Pipeline by Kythera Biopharmaceuticals, Inc., H1 2014
  • Lipid Disorders - Pipeline by Esperion Therapeutics, Inc., H1 2014
  • Lipid Disorders - Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Lipid Disorders Therapeutics - Recent Pipeline Updates, H1 2014
  • Lipid Disorders - Dormant Projects, H1 2014

List of Figures

  • Number of Products under Development for Lipid Disorders, H1 2014
  • Number of Products under Development for Lipid Disorders - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top